PCIB Stock Overview
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PCI Biotech Holding ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.81 |
| 52 Week High | kr3.40 |
| 52 Week Low | kr1.20 |
| Beta | 1.61 |
| 1 Month Change | 1.57% |
| 3 Month Change | -20.88% |
| 1 Year Change | -10.72% |
| 3 Year Change | -92.31% |
| 5 Year Change | -93.63% |
| Change since IPO | -89.96% |
Recent News & Updates
Recent updates
We're Keeping An Eye On PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Aug 05
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully
Apr 21We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely
Dec 16We're Not Very Worried About PCI Biotech Holding's (OB:PCIB) Cash Burn Rate
Apr 09What Type Of Shareholders Own The Most Number of PCI Biotech Holding ASA (OB:PCIB) Shares?
Feb 15PCI Biotech Holding (OB:PCIB) Is In A Good Position To Deliver On Growth Plans
Dec 22
Shareholder Returns
| PCIB | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -0.6% | -2.0% | 0.8% |
| 1Y | -10.7% | -72.5% | 3.1% |
Return vs Industry: PCIB exceeded the Norwegian Biotechs industry which returned -72% over the past year.
Return vs Market: PCIB underperformed the Norwegian Market which returned 4.4% over the past year.
Price Volatility
| PCIB volatility | |
|---|---|
| PCIB Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: PCIB's share price has been volatile over the past 3 months.
Volatility Over Time: PCIB's weekly volatility has decreased from 18% to 7% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Ronny Skuggedal | www.pcibiotech.com |
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.
PCI Biotech Holding ASA Fundamentals Summary
| PCIB fundamental statistics | |
|---|---|
| Market cap | kr67.49m |
| Earnings (TTM) | -kr20.31m |
| Revenue (TTM) | kr2.99m |
22.6x
P/S Ratio-3.3x
P/E RatioIs PCIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCIB income statement (TTM) | |
|---|---|
| Revenue | kr2.99m |
| Cost of Revenue | kr0 |
| Gross Profit | kr2.99m |
| Other Expenses | kr23.31m |
| Earnings | -kr20.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 100.00% |
| Net Profit Margin | -679.43% |
| Debt/Equity Ratio | 0% |
How did PCIB perform over the long term?
See historical performance and comparison